TM
TM
Hepatitis A (inactivated) and Typhoid Polysaccharide vaccine (adsorbed)
GSK’S TYPHOID-CONTAINING VACCINES ARE NOW BACK IN STOCK. AVAILABLE FOR FREE NEXT DAY DELIVERY* PLACE YOUR ORDER NOW.
YOU CAN VIEW AN INFORMATIVE WEBCAST ABOUT TYPHOID ON DEMAND ON
HEALTH.GSK USING THE FOLLOWING LINK:
http://hcp.gsk.co.uk/therapyareas/vaccines/expertperspectives/webcastsandvideos.html
(PLEASE NOTE THIS EDUCATIONAL VIDEO CONTAINS INFORMATION ABOUT GSK’S VACCINES AND IS SUITABLE ONLY FOR HEALTH CARE PROFESSIONALS) *Next day delivery is available for all existing vaccines account holders. For information on how to open an account, please contact GSK on 0808 100 9997
Typherix - Prescribing information Refer to Summary of Product Characteristics (SPC) before prescribing
Typherix. Typhoid Polysaccharide vaccine. Uses: Active immunisation against typhoid fever. Dosage and administration: For intramuscular (i.m.) injection. Adults and children (2 years and older): 0.5 ml (25µg Vi polysaccharide of Salmonella typhi Ty2 strain) at least 2 weeks prior to risk of exposure to typhoid fever. Subjects who remain at risk of typhoid fever should be revaccinated using a single dose of vaccine with an interval of not more than 3 years. Contra-indications: Hypersensitivity to any component. Postpone in acute severe febrile illness. Precautions: Appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic reaction following administration of the vaccine. Bleeding may occur following intramuscular injection to subjects with thrombocytopenia or bleeding disorders and firm pressure should be applied to the site (without rubbing) for at least two minutes for these subjects. Patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate response may not be achieved. Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints. Pregnancy and lactation: Typherix should only be used when there is high risk of infection. Adverse reactions: See SPC for full details. Clinical studies: Common: headache, nausea, itching, fever, general aches, malaise. Following a second dose, there was an increased incidence of redness and soreness (>10%). Post-marketing: Very rare: urticaria, anaphylaxis, allergic reactions including anaphylactoid reactions. Legal category: POM. Presentation and basic NHS cost: Typherix pre-filled 0.5 ml syringe. 1, £9.93; 10, £99.32. MA number:
PL 10592/0126. MA holder: SmithKline Beecham Ltd, Trading as GlaxoSmithKline UK, Stockley Park West, Uxbridge, UB11 1BT. Further information is available from: Customer Contact Centre, GlaxoSmithKline, Stockley Park West, Uxbridge, UB11 1BT;
customercontactuk@gsk.com; Freephone 0800 221 441. Typherix is a trademark of the GlaxoSmithKline group of companies. Date of Preparation: November 2013. UK/TYP/0001/12(1)
Hepatyrix - Prescribing information Refer to Summary of Product Characteristics (SPC) before prescribing
Hepatyrix. Hepatitis A (inactivated) and Typhoid Polysaccharide vaccine (adsorbed). Uses: Active immunisation against hepatitis A virus infection and typhoid fever. Dosage and administration: i.m. (deltoid) use. Adults and adolescents 15 years of age and older: 1 ml (containing Hepatitis A virus (HM175 strain) 1440 ELISA units and Vi polysaccharide of Salmonella typhi (Ty2 strain) 25 μg) at least 2 weeks prior to exposure to typhoid and hepatitis A. For long term hepatitis A protection, booster dose of an inactivated hepatitis A vaccine is recommended any time between 6-12 months after single dose of Hepatyrix. A single dose (1 ml) of Hepatyrix can be used as booster to hepatitis A vaccination between 6 and 12 months following primary immunisation with an inactive hepatitis A vaccine to subjects who also require protection against typhoid fever. A single dose (1 ml) Hepatyrix may be used to revaccinate against typhoid fever in subjects that also need to have a dose of hepatitis A vaccine. Revaccinate with typhoid Vi polysaccharide vaccine every 3 years if still at risk of typhoid fever. The vaccine should not be administered in the gluteal region and should under no circumstances be administered intravascularly.
In exceptional circumstances,
Hepatyrix may be administered subcutaneously to subjects with thrombocytopenia or bleeding disorders. Contra-indications: Hypersensitivity to any component or neomycin. Severe febrile
illness. Precautions: appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine. Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints. Adequate vaccine response may not be elicited in immunocompromised subjects and may require additional doses. It is not known whether Hepatyrix will prevent clinically apparent hepatitis A infections in subjects in the incubation period of hepatitis A at the time of vaccination. Pregnancy and lactation: Hepatyrix should only be used in pregnancy after careful consideration of the risk-benefit relationship and should only be used during breast-feeding when clearly needed. Adverse reactions: See SPC for full details. Very common: pain, erythema. Common: Headache, nausea, itching, fever, general aches, malaise, swelling. Very rare: allergic reactions (including anaphylaxis and anaphylactoid reactions), syncope, skin rashes. The following adverse reactions have been reported with GSK monovalent hepatitis A vaccine: Common: Loss of appetite, vomiting. Very rare: neurological manifestations including transverse myelitis, Guillain-Barre syndrome, neuralgic amyotrophy, convulsions, arthralgia, myalgia. Legal category: POM. Presentation and basic NHS cost: Hepatyrix pre-filled 1 ml syringe. 1, £37.21; 10, £372.10. MA number: PL 10592/0136. MA holder: SmithKline Beecham Ltd. Trading as GlaxoSmithKline UK, Stockley Park West, Uxbridge, UB11 1BT. Further information is available from: Customer Contact Centre, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT;
customercontactuk@gsk.com; Freephone 0800 221 441. Hepatyrix is a trademark of the GlaxoSmithKline group of companies. Date of preparation: January 2015 (UK/HEP/0001/15).
Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
Typherix and Hepatyrix are trademarks of the GlaxoSmithKline group of companies. © 2015 GlaxoSmithKline. All rights reserved.
UK/VAC/0004/15(1)b Date of preparation: October 2015
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56